DOCSLIB.ORG

903, 943 Ff., 958 F., 1025 – Organismic 686 F

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
903, 943 Ff., 958 F., 1025 – Organismic 686 F 1107 Index 14-3-3 108, 349 ff., 470 ff., 500, 529, 764 ff., AGC kinase 464 ff. 950 ff., 1057 agents – targeted 1079 a aging 17AAG (17-allylamino-17-demethoxygeld- – cellular 686 anamycin) 903, 943 ff., 958 f., 1025 – organismic 686 f. A20 108 AHA1 940 aberration AIDS 3, 67 – chromosomal 807 AIF (apoptosis inducing factor) 5, 205 ff., ACAMP, see apoptotic cell-associated 225 ff., 233 ff., 760, 850, 948 ff., 1059 molecular pattern – apoptotic function 238 acetylation 1015 ff. – cancer 249 acid sphingomyelinase (aSMase) 104, 997 f. – DNA fragmentation 246 actinomycin D 854 – down regulation 239 activation-induced cell death (AICD) – expression 234 10, 96 ff. – homolog 237 activin 495, 1099 – isoform 236 ACTR 1017 – release 241 acute myeloid leukemia (AML) 71, 419, – structure 234 917, 1018 AIF-homologous mitochondrion-associated acute promyelocytic leukemia 678, 1017 f. inducer of cell death (AMID), acyl-CoA-binding protein (ACBP) 210 see also p53-responsive gene 3 207, 237 adaptor protein (AP) AIF-like (AIFL) 207, 237 – AP-1 603 Akt, see protein kinase B – AP-2 603 aliphatic acids 1019 – AP-3 603 alkylating agent 799 – AP-4 603 alkylation therapy 842 adenine nucleotide translocator (ANT) alkyllysophospholipids (ALP) 1068 241, 286, 352, 578 alkylphosphocholines 1068 adenomatous polyposis alkyltransferase 799 – coli (APC) 176, 478 Alzheimerls disease 140 – familiarly adenomatous polyposis (FAP) aminopeptidase N (CD13) 112 syndrome 1073 aminophospholipid translocase 586 f. adenovirus amplification 164, 894, 973, 1018 – adenoviral gene transfer 903, 1035 AN-9 1026 – adenoviral vector-based system 852 anaplastic large cell lymphoma 678 – conditionally replicative 1035 androgen receptor (AR) 163 ff. – replication-selective 904 angiogenesis 17, 658, 714, 1064, 1087 f. adenylate kinase 2 (AK2) 209 – angiogenic switch 1090 adriamycin 607, 683, 906 – anti-angiogenic factor 1099 Apoptosis and Cancer Therapy. Edited by K.-M. Debatin and S. Fulda Copyright c 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN 3-527-31237-4 1108 Index – anti-angiogenic strategy, see inhibitors – MGMT triggered 802 of angiogenesis – modulator 1065 – pro-angiogenic factor 1091 – p53 influence on extrinsic and intrinsic angiopoietin 1095 pathway 519 ff. animal model 1080 – p53-mediated 1054 ankyrin repeat 446 – pathway 757 ff., 891 ff., 947 ff., 1049 ff. Annexin-I 587, 627, 654 – PKB 470 Annexin-V 713 – radiation sensitivity 1062 ansamycin 903 – radiation-induced 587 antennapedia 900 – Raf 497 f. antibody-TNF fusion protein 112 – ras-dependent protection 492 antisense – receptor pathway 850 – RNA technology 337 – regulation of DNA-damage-induced – oligonucleotide 853 apoptosis 273 – therapy 420 – resistance 1057 AP-1 814, 901 – shutdown of ATP-hydrolyzing enzyme Apaf-1, and RNA/protein synthesis 272 see apoptotic protease-activating factor-1 – signaling 4, 997 ff., 1049 ff. APO2L, – signaling kinase 1 (ASK1) 108, 504 see TNF-related apoptosis-inducing ligand – stress-induced 768 Apollon/BRUCE 227, 915 – TNF-induced apoptosis 560 apoptogenic protein 579 – TRAIL 40 apoptosis, see also programmed cell death –UV-C induced 805 3 ff., 156 ff., 282 ff., 382, 558, 658, 682 ff., apoptosis-inducing factor, see AIF 778, 799 ff., 849, 895 ff., 948, 997 ff., 1036, apoptosis-stimulating proteins of p53 1049 ff. (ASPP) 541 – antiapoptotic protein 13, 560 apoptosis signal-regulating kinase-1 – apoptosome 282 ff. (ASK-1) 108, 504, 767, 957 – apoptotic bodies 572 apoptosome 9, 190, 266 ff., 282 ff., 302, 321, – apoptotic cell clearance 625 ff., 648 ff. 609, 766 ff. – apoptotic cell-associated molecular pattern –Apaf-1 5, 266, 288 ff., 850 (ACAMP) 653 – cancer therapy 299 ff. – apoptotic chromatin condenser in the – caspase-9 5, 266 ff., 766 nucleus (ACINUS) 271 – embryonic development 298 – apoptotic threshold 1061 ff., 1079 – physiological regulation 296 – biochemical feature 271 ff. apoptotic protease-activating factor-1/ –Ca2+ 571 ff. apoptosis-promoting factor-1 (Apaf-1) 14, – caspase independent 851 104, 285 ff., 299 ff., 321 ff., 362, 406 ff., 490, – cell rounding and blebbing 272, 572 759 ff., 785 ff., 948 ff., 1074 – ceramide-induced 1054 ff. –Apaf-1-/- cell 957 – dexamethasone-induced 575 –Apaf-1-null mouse 298 – DNA damaging agents 799 ff. –Apaf-2, see cytochrome c – extrinsic pathway 4 ff., 406, 519, 718 – embryonic development 298 – FADD-dependent 1074 – interaction with Bcl-2 proteins 362 – genetics 692 APR, see Noxa – glucocorticoid-induced 574 apurinic/apyrimidinic site (AP site) 823 ff. – hypoxia-induced 778 ff. arachidonic acid (AA) 606, 1072 – internucleosomal degradation of DNA ARF, see p16INK4a/ARF (DNA fragmentation) 271, 320 Artemis 834 – intrinsic pathway 4 f., 346, 406, 520 ff., ARTS 204 718, 758 ASK1, see apoptosis signal-regulating – lucifearse-luciferin-system 718 kinase -1 – machinery 4 ff. ASK1-interacting protein (AIP) 108 – mitochondrial pathway 4, 850, 1024 ASM, see sphingomyelinase Index 1109 ataxia telangiectasia 687, 893 Bax/Bak 41, 104, 325, 346 ff., 363 ff., 502, – mutated protein (ATM) 678, 809 ff., 578 ff., 606, 765 ff., 782 ff., 828, 854, 948 ff. 831 ff., 893 ff. – activation 287, 523 ff. Ataxin-1 481 – adenine nucleotide translocator (ANT) ATF-6 790 352, 578 ATP depletion 110, 1059 – Bcl-2 family protein 1039, 1052 ff. ATR (kinase A-T and Rad3-related protein) – Bok 948 810, 826 ff., 839 – C-terminal tail 326 ATR-interacting protein (ATRIP) 840 –Ca2+ homeostasis 363 Aurora B kinase 429 – cancer 365 autoimmune disease 3, 67 – cleavage 349 autoimmune encephalomyelitis (EAE) 140 – conformation 349 ff. autoimmune lymphoproliferative syndrome – cyclophilin 352 (ALPS) 16, 37 – deregulation 334 autoimmunity 633 –ER 363 autophagic cell death 573 – hexokinase 352 autophagosome 603 – inhibitor 1 protein 576 autophagy 573, 603, 783, 851 – ion channel 352 – chaperone-mediated 603 – localization 363 – macroautophagy 603 – knockout mouse 356 – microautophagy 603 – mechanism 350 avian retrovirus 1039 – mitochondrial death pathway 1066 Axin 478 – mitochondrial pore 352 – mutation 14, 365 b – N-Bak 364 B cell 673 – oligomerization 326, 349 f. B cell lymphoma 14, 40, 419, 683, 762, 1018, – outer mitochondrial membrane 1058 1027 – p53-mediated upregulation 521, 901 – Bcl-2 overexpression 14 – proapoptotic 892 B chronic lymphocytic leukemia cell – redundancy 350 (B-CLL) 292 – splice variant 364 bacteria 998 – therapeutic opportunity 366 baculovirus IAP repeat (BIR) 198 ff., 223, – three-dimensional structure 353 407 ff., 427, 913 ff. – translocation 349 – domain 405, 878 ff., 918 ff. – voltage-dependent anion channel (VDAC) – domain antagonist 881 f. 352, 578 – second BIR domain (BIR2) 223, 918 ff. Bbc3, see Puma – Smac-binding pocket 925 Bcl-2 187, 318 ff., 330 ff., 346 ff., 382 ff., – small-molecule BIR2 antagonist 924 ff. 407 ff., 490 ff., 585, 678 ff., 758 ff., 850 ff., – small-molecule BIR3 antagonist 920 ff. 947 ff. – third BIR domain (BIR3) 223, 918 ff. – antiapoptotic protein 4, 41, 322 ff., 892, Bad 328, 470 ff., 499 f., 578, 762 ff., 782, 680 ff., 1063 ff. 854, 950 ff. – apoptosis 4, 40 –14-3-3 353, 470 – autophagy 573 – Bcl-2 family 1052 – Bax ratio 330 – heterodimerization 330 – BH3-only proteins 41, 379, 525 – phosphorylation 353 – cell death 572 – proapoptotic 1025, 1057 – cell survival 583 Bag (Bcl-2 interacting protein) 500, 939 ff., – family 758 ff., 783, 892, 947 ff., 1038 f., 956 1052 BAP (Bcl-2-associated protein) 576 f. – homology (BH) domain 8, 286, 322 ff., base excision repair (BER) 799 ff., 823 ff. 348 ff., 383, 762, 947 basic helix-loop-helix (bHLH)-PAS – interacting protein (Bag) 500, 939 ff., 956 transcription factor family 781 – interaction 356 1110 Index – Noxa 379 – regulation 357 – outer mitochondrial membrane (OMM) – splice variant 364 integrity 225 – structure 355 – overexpression 240, 323 ff., 490, 585, 614, – targeting 355 685, 1058 ff., 1074 – therapeutic opportunity 366 – p53 influence 520 ff. – truncated (tBid) 41, 476, 578, 764, 1052 f. – proapoptotic protein 4, 41, 241, 892 – ubiquitination 358 – prosurvival 322 ff., 759 Bik (Bcl-2-interacting killer) 762, 1039 –Puma 379 Bim 327 f., 364, 392, 501, 762 ff., 951, 1052 – targeted expression 1053 – BimEL 762 Bcl-2-associated protein, see BAP biological modifier 691 Bcl-2-interacting killer, see Bik bioluminescence imaging 688 f., 709 f. Bcl-3 446 BIP 955 Bcl-W 325, 1052 BIR, see baculovirus IAP repeat Bcl-XL 286, 325 ff., 350, 503, 583, 759 ff., BL1521 1020 854, 949, 1025, 1052 ff. Bloom’s syndrome (BS) protein (BLM) 836 ff. – three-dimensional structure 338 Bmf 328, 763 Bcl-XS 764 BNip3 762, 783 f. BCR-ABL 672 ff., 905, 1025 – BNip3-like (BNip3L) 783 f. behacizumab 686 Bok 764, 948 benzamides 1019 bone marrow transplantation (BMT) 71 benzoquinone 903 bone morphogenetic protein (BMP) 494 Bergerat fold 939 ff. bortezomib (PS-341) 1025, 1075 betulinic acid 1067 ff. breast cancer 419, 588 BH1 286, 322 ff., 348 ff., 383, 947 – BRCA1 835 ff., 1018 BH1-3 (multidomain) group 758 ff. – BRCA2 835 ff. BH2 286, 322 ff., 348 ff., 383, 947 Burkitt’s lymphoma 672 BH3 8, 286, 322 ff., 348 ff., 383, 762, 783, 947 butyric acid 1026 – peptide 854 bystander cell 686 – protein 947 f. – three-dimensional structure 353 c BH3 mimetic 338 C225 (Erbituxr, cetuximab) 1050, 1069 BH3-containing protein 470, 787 C-reactive protein 653 BH3-only proteins 187, 287, 327 ff., 353, C-terminal modulator protein (CTMP) 469 379 ff., 501, 578, 758 ff., 854 Ca2+ 1054 ff. – post-translational modification 353 – compartmentalization 573 – regulation 328 – ER-dependent release 244, 790, 1073 BH4 286, 322 ff., 348 ff., 383, 947 – extrusion 573 Bid (BH3-interacting domain) 104, 270 f., – homeostasis 571, 588 328, 346 ff., 360 ff., 584, 606, 762 ff., 782, – hotspot 577 851, 949 ff., 1038, 1052 – overload 572 ff. – bid-deficient mouse 358 – storage 573 ff. – C-terminal (tcBid) 360 – store-operated influx 588 – cancer 365 CAD, see caspase-activated DNase – cardiolipin 361 Caenorhabditis elegans 240, 317 ff., 633, – cathepsin 358 692, 945 – cleavage 354 ff., 1037 calcineurin 578 ff.
Load more

Recommended publications
  • Rheumatoid Arthritis a Virus Disease?
    J Clin Pathol: first published as 10.1136/jcp.s3-12.1.132 on 1 January 1978. Downloaded from J. clin. Path., 31, Suppl. (Roy. Coll. Path.), 12, 132-143 Inflammation and fibrosis Rheumatoid arthritis a virus disease? A. M. DENMAN From the Division ofImmunological Medicine, Clinical Research Centre, Harrow, Middlesex We now understand many of the immunopatho- arteritis with perivascular infiltrates of chronic logical processes that damage joints and other inflammatory cells, and aberrant immune responses. structures in rheumatoid arthritis and diffuse con- Secondly, virus-infected cells initiate the whole nective tissue diseases. Unfortunately, our progress spectrum of inflammatory and immune reactions in this direction is matched by an equal failure to which characterise the human disorders. These identify the causes of all but a few of these disorders. include complement activation by the classical and Nevertheless, the stimuli which initiate these diseases alternative pathways, which in turn initiate such are probably commonly encountered and tissue processes as the immediate hypersensitivity reaction, damage results when these immunopathological platelet aggregation, and the chemotaxis of granulo- processes are abnormal in intensity and duration- cytes and mononuclear phagocytes. Furthermore, in other words, disease follows an unusual host virus-infected cells attract antibody either through reaction to a variety of environmental factors. This virus-coded antigens on the cell membrane or principle is well illustrated by the degenerative because infected cells commonly carry receptors for copyright. disease of the central nervous system, subacute the Fc portion of the immunoglobulin molecule. sclerosing panencephalitis, which ensues in in- These cells also attract a cellular response in the dividuals who are unable to control the growth form of both specifically sensitised T lymphocytes and dissemination of measles virus.
    [Show full text]
  • Barriers to Adoption of GM Crops
    Iowa State University Capstones, Theses and Creative Components Dissertations Fall 2021 Barriers to Adoption of GM Crops Madeline Esquivel Follow this and additional works at: https://lib.dr.iastate.edu/creativecomponents Part of the Agricultural Education Commons Recommended Citation Esquivel, Madeline, "Barriers to Adoption of GM Crops" (2021). Creative Components. 731. https://lib.dr.iastate.edu/creativecomponents/731 This Creative Component is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Creative Components by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Barriers to Adoption of GM Crops By Madeline M. Esquivel A Creative Component submitted to the Graduate Faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Plant Breeding Program of Study Committee: Walter Suza, Major Professor Thomas Lübberstedt Iowa State University Ames, Iowa 2021 1 Contents 1. Introduction ................................................................................................................................. 3 2. What is a Genetically Modified Organism?................................................................................ 9 2.1 The Development of Modern Varieties and Genetically Modified Crops .......................... 10 2.2 GM vs Traditional Breeding: How Are GM Crops Produced?
    [Show full text]
  • Prostate Cancer Chemoprevention Agents Exhibit Selective Activity Against Early Stage Prostate Cancer Cells
    Prostate Cancer and Prostatic Diseases (2001) 4, 81±91 ß 2001 Nature Publishing Group All rights reserved 1365±7852/01 $15.00 www.nature.com/pcan Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells YQ Liu1, E Kyle2, S Patel2, F Housseau3, F Hakim2, R Lieberman4, M Pins5, MV Blagosklonny2 & RC Bergan1* 1Division of Hematology/Oncology, Department of Medicine, Northwest University Medical School and the Robert H. Lurie Cancer Center of Northwestern University, Chicago, USA; 2Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, National Institutes, National Institutes USA; 3Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; 4Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; and 5Department of Pathology, Northwestern University Medical School and the Robert H. Lurie Cancer Center of Northwestern University, Chicago, USA Preclinical models for the identi®cation of prostate cancer chemoprevention agents are lacking. Based upon the notion that clinically useful chemoprevention agents should exhibit selective activity against early stage disease, studies were undertaken to assess whether chemoprevention agents selectively inhibited the growth of early stage prostate cancer, as compared to late stage cancer. First, a series of cell and molecular studies were performed, which, when taken together, validated the use of a panel of prostate cell lines as a model of the different stages of carcinogenesis. Next, therapeutic responsiveness to ten different cytotoxic or chemoprevention agents was evaluated. Chemoprevention agents exhibited selective activity against normal and early transformed prostate tissue, whereas cytotoxic agents were non-speci®c. Selective activity against early versus advanced prostate cancer cells is identi®ed as a potential screening method for chemoprevention agents.
    [Show full text]
  • Viral Transformation
    Proc. Natl. Acad. Sci. USA Vol. 75, No. 5, pp. 2473-2477, May 1978 Microbiology New region of the simian virus 40 genome required for efficient viral transformation (viable deletion mutants/soft agar assay/small t antigen) NOEL BOUCK*, NADINE BEALES*, THOMAS SHENK , PAUL BERGf, AND GIAMPIERO DI MAYORCA* * Department of Microbiology, University of Illinois at the Medical Center, Chicago, Illinois 60680; t Department of Microbiology, University of Connecticut Health Center, Farmington, Connecticut 06032; and * Department of Biochemistry, Stanford University Medical Center, Stanford, California 94305 Contributed by Paul Berg, February 13,1978 ABSTRACT Viable mutants of simian virus 40 with dele- deletions in the proximal part of the early region affect a dif- tions in three regions of the virus genome (map coordinates ferent function than the one altered in the ts A mutants. 0.21-0.17, 0.59-0.54, and 0.67-0.74) have been tested for their ability to transform rat fibroblasts to anchorage independence. MATERIALS AND METHODS Only those mutants whose deletions occur between 0.59 and 0.55 in the proximal part of the early region are defective in trans- Cells and Viruses. Fischer rat line Fill (15), kindly sent to forming ability. The most severely defective of these transform us by A. Freeman, and passaged less than 25 times, was used with less than one-hundredth the efficiency of wild type. They for most transformation experiments. Chinese hamster lung retain their defect when tested in Chinese hamster lung cells cells, CHL (7), were obtained from R. Martin. The monkey and when infection is initiated with viral DNA instead of intact line BSC-1 was used virions.
    [Show full text]
  • Wo 2008/048344 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 24 April 2008 (24.04.2008) PCT WO 2008/048344 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/34 (2006.01) C12N 15/10 (2006.01) kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, (21) International Application Number: CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, PCT/US2007/003948 GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, (22) International Filing Date: JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, 13 February 2007 (13.02.2007) LT, LU, LV,LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, (25) Filing Language: English RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (26) Publication Language: English (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 60/773,255 13 February 2006 (13.02.2006) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): FRAUN- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), HOFER USA, INC.
    [Show full text]
  • Selective Inhibition of Growth of Transformed Cells by Protease Inhibitors* (Contact Inhibition/Mouse/Hamster)
    Proc. Nat. Acad. Sci. USA Vol. 69, No. 12, pp. 3825-3827, December 1972 Selective Inhibition of Growth of Transformed Cells by Protease Inhibitors* (contact inhibition/mouse/hamster) HANS PETER SCHNEBLIt AND MAX M. BURGER$ t Friedrich Miescher-Institute, P.O. Box 273, CH4002 Basel, Switzerland; and Princeton University, Department of Biochemical Sciences, Princeton, New Jersey 08540 Communicated by Vladimir Prelog, September 26, 1972 ABSTRACT Five protease inhibitors with different All cells were grown in Dulbecco's modified Eagle's Medium modes of action were found to reduce the growth of trans- (Gibco No. H-16) containing 10% fetal-calf serum (Micro- formed mouse (Py3T3, SV3T3, and 3T12) and hamster (PyBHK) cells. Some of these inhibitors caused the trans- biological Assoc., Bethesda, Md.). Stocks were passaged two formed cells to cease growth at saturation densities charac- to three times weekly, and care was taken to keep normal teristic for nontransformed cells. cells at low densities. Cells were checked for pleuropneumonia- The protease inhibitors were strikingly selective with like organisms regularly and were free of contamination regard to the transformed cells; they had essentially no the effect on the growth of the nontransformed cells. From throughout study. this result, it is concluded that the inhibitors block a pro- Cell growth curves in the presence or absence of protease tease-like activity that is required for the unrestrained inhibitors were obtained as follows: the cells were plated in growth of transformed cells. 3.5-cm petri dishes (Falcon) 48 hr before addition of the in- The inhibitors exerted their effect directly on the cells; hibitors.
    [Show full text]
  • Chapter 6 - Virology Viruses in Action!!
    Chapter 6 - Virology Viruses in Action!! • Topics – Structure – Classification – Multiplication – Cultivation and replication – Nonviral infectious agent – Teratogenic/Oncogenic - Viruses have a host range. That is, viruses infect specific cells or tissues of specific hosts, or specific bacteria, Human or specific plants. Rhinovirus Common - Viral specificity refers to the specific Cold kinds of cells a virus can infect. It is regulated by the specificities of attachment, penetration and replication of the virus Properties of viruses A virion is an infectious virus particle - not all virus Viruses are not cells, do not have nuclei or particles are infectious mitochondria or ribosomes or other cellular Viruses are composed of a nucleic acid, RNA or DNA components. - never both . Viruses replicate or multiply. Viruses do not grow. All viruses have a protein coat or shell that surrounds Viruses replicate or multiply only within living cells. and protects the nucleic acid core. Viruses are obligate intracellular parasites . Some viruses have a lipid envelope or membrane surrounding a nucleocapsid core. The source of the The term virus was coined by Pasteur, and is from envelope is from the membranes of the host cell. the Latin word for poison. Some viruses package enzymes - e.g. RNA- Components of viruses - dependent-RNA polymerase or other enzymes - some do not package enzymes 1 Size comparison of viruses - how big are they? Structure • Size and morphology • Capsid • Envelope • Complex • Nucleic acid Mycoplasma? There are two major structures
    [Show full text]
  • UNIT-I DNA: Definition, Structure & Discovery DNA
    SRINIVASAN ARTS AND SCIENCE COLLEGE (CO-ED) PERAMBALUlR - 621212 DEPARTMENT OF BIOTECHNOLOGY CLASS : I M.SC., BIOTECHNOLOGY SUBJECT: rDNA TECHNOLOGY SUB CODE : P16BT21 UNIT-I DNA: Definition, Structure & Discovery DNA The structure of the DNA double helix. The atoms in the structure are colour-coded by element and the detailed structures of two base pairs are shown in the bottom right. The structure of part of a DNA double helix Deoxyribonucleic acid is a molecule composed of two polynucleotide chains that coil around each other to form a double helix carrying genetic instructions for the development, functioning, growth and reproduction of all known organisms and many viruses. DNA and ribonucleic acid (RNA) are nucleic acids. Alongside proteins, lipids and complex carbohydrates (polysaccharides), nucleic acids are one of the four major types of macromolecules that are essential for all known forms of life. The two DNA strands are known as polynucleotides as they are composed of simpler monomeric units called nucleotides. Each nucleotide is composed of one of four nitrogen-containing nucleobases (cytosine [C], guanine [G], adenine [A] or thymine [T]), a sugar called deoxyribose, and a phosphate group. The nucleotides are joined to one another in a chain by covalent bonds (known as the phospho-diester linkage) between the sugar of one nucleotide and the phosphate of the next, resulting in an alternating sugar-phosphate backbone. The nitrogenous bases of the two separate polynucleotide strands are bound together, according to base pairing rules (A with T and C with G), with hydrogen bonds to make double- stranded DNA. The complementary nitrogenous bases are divided into two groups, pyrimidines and purines.
    [Show full text]
  • Copy of Growing Into Their
    Growing into their Own? Plant Molecular Farming and the Pursuit of Biotechnological Sovereignty for Lower and Middle Income Countries. Ana Christine Zeghibe Submitted in Partial Fulfillment of the Prerequisite for Honors In Biological Sciences Under the advisement of Martina Koniger, Ph.D. Wellesley College May 2021 © 2021 Ana Zeghibe Acknowledgements I am extraordinarily grateful for the support, kindness and guidance of my major and thesis advisor Professor Martina Koniger. The strong plant biology influence on an otherwise biotechnologically and medically oriented thesis was largely inspired by her own expertise in chloroplasts. When coming to this thesis, I knew I wanted to write something that was not simply a research paper, but a synthesis of ideas and observations about science and its interactions with the world beyond the laboratory that I had made over my 4 years at Wellesley. Thank you, as always, for allowing me to develop this unusual project, for keeping me sane through the many pitfalls and trials of writing, and for making me fall in love with science communication and plant biology. Thank you to my committee member Professor Natali Valdez for supporting and guiding my analyses and thoughts on the societal implications of plant molecular pharming. Professor Valdez's classes and work in Feminist Science and Technology Studies strongly influenced the later chapters of this thesis, helping me to think about the hopeful possibilities and critical realities for humanitarian applications of this unusual biotechnology. I am extremely thankful for her critiques of my argument and writing, her insight into the existing literature on biotechnological sovereignty and her passion for this project's potential.
    [Show full text]
  • Problem of Genetically Modified Foods Safety: a Toxicologist’S View
    REVIEWS UDC 604.6 doi: 10.15407/biotech9.01.007 PROBLEM OF GENETICALLY MODIFIED FOODS SAFETY: A TOXICOLOGIST’S VIEW E. L. LEVITSKY Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, Kiyv E-mail: [email protected] Received 20.10.2015 This study aimed to analyze the published literature regarding the problem of safety of consuming food products containing genetically modified organisms. Genetically modified food products are given a brief definition, purpose and methods of their production are described, and the pro- and contra- arguments for their consumption are presented. The discussion is mostly focused on results of evaluating possible toxicity of such foods and their safety for macroorganism using traditional methods of toxicological analysis. Test results for long-term toxic effects, namely allergenicity, carcinogenicity, reproductive toxicity, and the possibility of mutagenic effects of these food products on the human body and the intestinal microflora are discussed separately. These data are based on the current understanding of the laws of the penetration and functioning of foreign genetic material outside the body, its entry and the possibility of integration into the genome during intake of foods manufactured by genetic engineering. The basic principles of the toxicological and hygienic regulation of these food products are also considered. An analysis of published experimental results allowed to draw a general conclusion about the absence of reliable scientific information indicating the presence of the toxic properties of genetically modified foods, and therefore of credible evidence of the dangers of consuming for humans and pets. Key words: genetically modified foods, toxicity, safety.
    [Show full text]
  • Transformation and Oncogenesis Lecture 18 Biology 3310/4310 Virology Spring 2017
    Transformation and Oncogenesis Lecture 18 Biology 3310/4310 Virology Spring 2017 Cause and effect, means and ends, seed and fruit, cannot be severed; for the effect already blooms in the cause, the end pre- exists in the means, the fruit in the seed. RALPH WALDO EMERSON Transformation Virology Lectures 2017 • Prof. Vincent Racaniello • Columbia University Principles of Virology, ASM Press The puzzling properties of transformed cells in the laboratory • Immortal: Grow indefinitely (HeLa) • Loss of anchorage dependence • Loss of contact inhibition • Colony formation in semi-solid media • Decreased requirements for growth factors (serum) Virology Lectures 2017 • Prof. Vincent Racaniello • Columbia University Oncogenesis • Development of cancer - Tumor: swelling caused by abnormal growth of tissue, benign or malignant • Cancer is a genetic disease • 8.2 million deaths/yr developed countries • Mutations (~12) affect signal transduction pathways that govern cell proliferation, survival, determination of cell fate, maintenance of genome integrity • Mutations may be inherited, caused by DNA damage, environmental carcinogens, infectious agents including viruses Virology Lectures 2017 • Prof. Vincent Racaniello • Columbia University Transformation and oncogenesis are distinct Requires additional genetic changes May not be oncogenic • Studying virus-transformed cells provides insight into molecular events that establish oncogenic potential • No virus can do it all Virology Lectures 2017 • Prof. Vincent Racaniello • Columbia University Human cancer viruses
    [Show full text]
  • Review on the Role of the Human Polyomavirus JC in the Development of Tumors Serena Delbue1* , Manola Comar2,3 and Pasquale Ferrante1,4
    Delbue et al. Infectious Agents and Cancer (2017) 12:10 DOI 10.1186/s13027-017-0122-0 REVIEW Open Access Review on the role of the human Polyomavirus JC in the development of tumors Serena Delbue1* , Manola Comar2,3 and Pasquale Ferrante1,4 Abstract Almost one fifth of human cancers worldwide are associated with infectious agents, either bacteria or viruses, and this makes the possible association between infections and tumors a relevant research issue. We focused our attention on the human Polyomavirus JC (JCPyV), that is a small, naked DNA virus, belonging to the Polyomaviridae family. It is the recognized etiological agent of the Progressive Multifocal Leukoencephalopathy (PML), a fatal demyelinating disease, occurring in immunosuppressed individuals. JCPyV is able to induce cell transformation in vitro when infecting non-permissive cells, that do not support viral replication and JCPyV inoculation into small animal models and non human primates drives to tumor formation. The molecular mechanisms involved in JCPyV oncogenesis have been extensively studied: the main oncogenic viral protein is the large tumor antigen (T-Ag), that is able to bind, among other cellular factors, both Retinoblastoma protein (pRb) and p53 and to dysregulate the cell cycle, but also the early proteins small tumor antigen (t-Ag) and Agnoprotein appear to cooperate in the process of cell transformation. Consequently, it is not surprising that JCPyV genomic sequences and protein expression have been detected in Central Nervous System (CNS) tumors and colon cancer and an association between this virus and several brain and non CNS-tumors has been proposed. However, the significances of these findings are under debate because there is still insufficient evidence of a casual association between JCPyV and solid cancer development.
    [Show full text]